Skin & hair

When Acne Returns After Isotretinoin

Save

A single course of isotretinoin clears acne for a large majority of people, but "clears" and "cures forever" are not the same claim. This looks at why relapse happens, what raises the odds of it, what retrying the drug involves, and what else is on the table if it isn't the right second step.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why Relapse Happens at All

Isotretinoin works by shrinking the oil glands that drive acne, and for most people who complete a full course, that effect holds well after the medication stops — systematic review evidence supports its effectiveness for the acne it's typically prescribed for, alongside a well-characterized profile of skin and mucous membrane side effects during treatment 1. Relapse, when it happens, usually isn't a sign the drug failed; it more often reflects that the oil glands regained some activity once the drug-driven shrinkage wasn't being actively maintained.

That distinction matters for how relapse gets talked about with a prescriber: framing it as "the treatment stopped working permanently" and framing it as "the underlying oil-gland activity partly returned" point toward different next steps, and the second framing is closer to what the evidence actually describes, which is why a relapse conversation with a dermatologist usually starts with what changed, not with whether the first course was a failure.

Isotretinoin Treats Severity, Not the Underlying Driver

Isotretinoin is generally reserved, under current guideline recommendations, for acne that is severe, scarring, psychosocially burdensome, or has not responded to other treatments 2 — which means the population that gets prescribed it in the first place already tends to have acne with strong underlying drivers, hormonal or otherwise, that don't necessarily disappear just because the drug was effective for a while. A course that clears skin completely doesn't reset those underlying drivers to zero.

This is worth sitting with precisely because isotretinoin often gets talked about as a one-time fix, and for a real share of people it is. But going in with the more accurate expectation — that it's a highly effective treatment for a specific severity of disease, not a guaranteed permanent cure — makes a later relapse land as expected rather than as a failure.

Who Relapses More Often

A few patterns show up repeatedly in who relapses. Younger age at the time of treatment — particularly adolescence, when oil-gland activity is still changing with puberty — is associated with a higher chance of acne returning later. A lower total cumulative dose across the course, relative to body weight, is associated with more relapse in the evidence base than a fuller course completed at a higher cumulative exposure, which is part of why a dermatologist may recommend completing the full planned course even after skin looks clear partway through. Truncal acne and clearly hormonal patterns — jawline-dominant breakouts, flares tied to the menstrual cycle — also relapse more often than purely facial, non-hormonal acne.

None of these factors predict relapse with certainty for any one person; they describe a pattern across many people treated, not a forecast for a specific case. Someone with several of these features can still stay clear for years, and someone with none of them can still see acne return — the factors shift probability, not certainty.

Retrying Isotretinoin

Retrying isotretinoin is a real and common option, and it requires going through the full iPLEDGE process again, not simply refilling a prescription. Because isotretinoin is teratogenic, every course — first or repeat — requires prescriber, patient, and pharmacy registration through the FDA's risk mitigation program, along with pregnancy-prevention requirements for anyone who can become pregnant 3. People sometimes worry that a repeat course carries escalating risk, but large-scale data specifically examining a widely-feared long-term concern — inflammatory bowel disease — has not found a clinically meaningful increased risk associated with isotretinoin use 4, which is worth knowing when weighing a second course.

The registration burden of a second course surprises some people who remember the first course as a one-time hurdle; it isn't waived for a repeat prescription, and rebuilding familiarity with the monthly requirements takes some of the same adjustment the first course did.

Options Besides a Second Course

When isotretinoin isn't the right next step — because of timing, side effects during the first course, or simply not wanting to repeat it — other options target the same drivers a retrial would. For hormonally-driven acne in women, oral spironolactone has randomized trial evidence supporting improvement over placebo 5 and is a common next step precisely for the truncal-and-jawline pattern that tends to relapse. Topical maintenance therapy is the other major lever: a fixed-dose combination of a retinoid and benzoyl peroxide has evidence supporting better and faster results than either ingredient used alone 6, and is frequently what a dermatologist reaches for to hold the line between isotretinoin courses or in place of a second one.

Neither of these options works the same way isotretinoin does, and neither is a drop-in replacement — they're different tools aimed at different pieces of the same underlying problem, and a dermatologist weighing them is looking at which driver, hormonal versus surface oil and turnover, seems to be doing the most work in a given relapse.

Preventing Relapse Before It Starts

Whether or not relapse happens at all is partly shaped by what comes immediately after the isotretinoin course ends, not just the course itself. A period of no active treatment right after finishing isotretinoin is when relapse risk shows up first for people prone to it, which is why some dermatologists start a topical retinoid as maintenance therapy once the course is done, aiming to hold the oil-gland changes isotretinoin produced rather than waiting for acne to visibly return before restarting any treatment at all.

Bringing up maintenance therapy proactively, before the final isotretinoin follow-up visit ends, is a reasonable thing to raise directly — it's a small conversation that shifts the plan from reactive to preventive, and it costs nothing to ask whether a maintenance step makes sense for a specific case.

Common questions

Most people who complete a full course see acne stay substantially clearer for years, but relapse isn't rare either, and certain groups — people treated at a younger age, those with hormonally-driven or truncal acne, and anyone whose course ended at a lower cumulative dose — see it more often. There's no single number that applies to everyone, since it depends heavily on which of these factors are in play.

The evidence base associates a lower total cumulative dose across a course with a higher chance of relapse compared with completing a fuller course, which is one reason a dermatologist may recommend finishing the full planned course even once skin looks clear. This is a general pattern in the evidence, not a guarantee for any individual course.

A second course goes through the same iPLEDGE registration and safety requirements as the first, since the pregnancy-prevention rules apply to every course regardless of how many came before. Large studies looking specifically at a commonly-feared long-term risk, inflammatory bowel disease, have not found a meaningful increased risk tied to isotretinoin use, which is often a starting point for that conversation with a prescriber.

For hormonally-driven acne in women, oral spironolactone has trial evidence supporting it as an option. Topical maintenance with a combination retinoid and benzoyl peroxide is another well-supported approach, often used specifically to hold results between courses or instead of a second course altogether.

That's a conversation for whoever is treating the relapse, since it depends on how the return compares to what the acne looked like before the original course and how quickly it's progressing. Starting a maintenance topical proactively, rather than waiting for a full relapse to unfold, is a common approach precisely because it tends to be easier to hold a clear result than to reclaim one.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When a Relapse Needs More Than a Waiting Game

  • —new cysts or nodules leaving scars, especially if scarring wasn't happening before
  • —acne flaring alongside signs of a hormonal condition — irregular cycles, new excess hair growth, or rapid weight change
  • —low mood, new depression, or thoughts of self-harm during or after any acne treatment

Thoughts of self-harm are a 988 or 911 emergency.

This article explains general patterns in acne relapse after isotretinoin and is not medical advice; it does not recommend a treatment plan for any individual.

References

  1. 1.Costa CS, Bagatin E, Martimbianco ALC, et al. (2018). Oral isotretinoin for acne. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD009435.pub2Cochrane review of isotretinoin's efficacy and adverse-effect profile for acne vulgaris, supporting general statements about its effectiveness and side-effect characterization.
  2. 2.Reynolds RV, Yeung H, Cheng CE, et al. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. PMID 38300170 ✓AAD guideline strongly recommends isotretinoin for severe, scarring, psychosocially burdensome, or refractory acne, supporting that isotretinoin is reserved for a specific severity tier rather than used as a universal cure.
  3. 3.U.S. Food and Drug Administration (2023). iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). U.S. Food and Drug Administration. link ✓Isotretinoin is teratogenic and dispensed only through the FDA-mandated iPLEDGE REMS, which requires prescriber, patient, and pharmacy registration for every course, including a repeat course.
  4. 4.Tan NKW, Tang A, Lim RK, et al. (2023). Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study. Journal of the American Academy of Dermatology. PMID 36529376 ✓Large-scale study finding isotretinoin is not associated with a clinically meaningful increased risk of inflammatory bowel disease, relevant reassurance when considering a repeat course.
  5. 5.Santer M, Lawrence M, Renz S, et al. (2023). Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. PMID 37192767 ✓Randomized placebo-controlled trial showing oral spironolactone improves acne severity in women, supporting it as an off-label hormonal option for relapsed or hormonally-driven acne.
  6. 6.McKeage K, Keating GM (2011). Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years. American Journal of Clinical Dermatology. PMID 21967116 ✓Fixed-dose adapalene/benzoyl peroxide combination gel outperforms either ingredient alone, supporting its use as topical maintenance therapy after an isotretinoin course.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library